PMD2 Admission to Coronary Angiographic Catheterization in Armenia at Nork Marash Medical Center: Characteristics and Outcomes  by Perikhanyan, A.
indicators for the Clearing House and the measures could complement indicators
on clinical quality of providers from the NIH Promis initiative in the United States
(or the NHS Proms in the UK).METHODS: The concept development is relevant for
chronic care. Five domains represent outpatient drug care: information, commu-
nication access, trust and clinical quality. Four process measures and one access
measure are proposed with series of 5 -7 items, tested on pharmacy delivery sys-
tems and dispensing doctors.The trust indicator has been identified as critical for
the US drug delivery system and discussed as an example. RESULTS: Trust ad-
resses the potential patient mistrust when cost interfere with clinical judgement.
The process measure is calculated for prescribing and treatment decisions for
Hypertension, Diabetes and Asthma.It is a rate base measure . The Facct scoring
method is modified to integrate minima in low score values. Mean scores are cal-
culated on samples per practice. Missing values are replaced by mean value. The
evidence from the UK PCT on a scale of 0-100, for three practices show scores of
66.78; 63.82;73.92 and 67.72 for the whole sample with a Cronbach of 0.70.
CONCLUSIONS:A composite indicator is envisaged for diffferent decision points in
clinical practices. It is to be linked to clinical decision points from the Adaptive
Knowledge Platform (AKP) (Huttin, Liebamn, 2011) on breast cancer and could fit
the requirements for the 12 rules for EGD in cancer. Validations in additional or-
ganisations of care and delivery systems are planned in further validation stages.
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OBJECTIVES: To serve as comparative data for percutaneous valve replacements,
this study sought to characterize the historical outcomes for aortic andmitral valve
replacement surgery in a large, nationally representative population. METHODS:
Patients undergoing aortic ormitral valve replacement were identified from the 5%
national Medicare data (1997-2009) using ICD-9-CM codes 35.21 to 35.24. The sub-
sequent rates of mortality, mechanical complications, infection, and valve re-im-
plantation/reoperation, and infective endocarditis were evaluated. Hospitalization
charges and reimbursements (in Jan 2011 dollars) for the index procedurewere also
assessed. RESULTS: The patient cohort included 12,202 aortic bioprosthesis, 9,757
aortic mechanical valves, 3,222 mitral bioprosthesis, and 4,401 mitral mechanical
valves. The ten-year Kaplan-Meier mortality, mechanical complication, infection,
re-implantation/reoperation, and infective endocarditis rates for aortic biopros-
thesis were 64.4%, 4.41%, 4.54%, 1.50%, and 8.34%, respectively, and for aortic me-
chanical valves were 63.9%, 5.23%, 4.71%, 1.84%, and 9.08%, respectively. The cor-
responding ten-year Kaplan-Meier rates formitral bioprosthesiswere 74.8%, 8.02%,
6.29%, 2.81%, and 12.90%, respectively, and for mitral mechanical valves were
64.7%, 7.60%, 6.06%, 2.87%, and 12.24%, respectively. The average hospitalization
reimbursements for procedures involving aortic bioprostheses, aortic mechanical
valves, mitral bioprostheses, and mitral mechanical valves were $54.3k, $54.6k,
$64.1k, and $62.2k, respectively. CONCLUSIONS: The crude risks of mortality and
complications, as well as payer costs, were found to be higher for mitral valve
replacements compared with aortic valve replacements. This study provides base-
line data for evaluating the comparative effectiveness of percutaneous valve re-
placement to “traditional” approaches, especially since the percutaneous ap-
proach may have inherently different levels of performance or expanded
indications.
PMD2
ADMISSION TO CORONARY ANGIOGRAPHIC CATHETERIZATION IN ARMENIA
AT NORK MARASH MEDICAL CENTER: CHARACTERISTICS AND OUTCOMES
Perikhanyan A
Nork Marash Medical Center, Yerevan, Armenia
OBJECTIVES: The importance of avoiding unnecessary diagnostic invasive angiog-
raphy is emphasized based on risks associated with test and costs. At the same
time, early interventions are important to reduce negative outcomes of coronary
artery disease (CAD). Objective of this study was to analyze the characteristics and
outcomes of cases with possible CAD that underwent coronary angiography cath-
eterization (CAG) from December 2006 to February 2007 consecutively in Nork
Marash Medical Center (NMMC). METHODS: This was a retrospective study of
newly admitted cohort. Predefined exclusion criteria were CAG in other clinic, CAG
for other then CAD reasons and non Armenian residency. RESULTS: Only 200 re-
cordswere corresponding to the criteria. Themean age of caseswas 52.9110 years
and 85% were males (RR0.93). The mean age of women was higher (60 vs 50).
Only 10.5% of participants had normal BMI. Current smokers comprised 60 %(
RR1.17), 74% had hypertension (RR1.165), 30.5% hypercholesterolemia (RR2.5)
and 14.5%DiabetesMellitus (RR4.26). In 26(13%) cases catheterization detected no
CAD at all and 13(6.5%) patients had stenosis50%. Most catheterizations were
elective (68%).There were 2 urgent admissions among patients with CAD50%.
Significantly diseased left anterior descending (LAD) proximal was detected most
frequently (52%).Among patients with stenosis50% 24% of cases underwent PCI,
75% CABG, and 5% bridge to CABG procedure. Thirty two people (20%) were not
treated with revascularization: among them 7 (21.9%) with multivessel disease.
15% of patients with indication to revascularization refused to be treated with any
of procedures. CONCLUSIONS: There is gender inequality in CAG utilization, early
cholesterol control should be encouraged by primary care professionals, patient
preferences play significant role in a treatment decision process in Armenia.
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OBJECTIVES: To differentiate three types of Mechanical Neck Disorders (MND) by
Current Perception Threshold (CPT). Specific aims were to: 1) Look whether differ-
ences in CPT exist in MND categories, and 2) Estimate the predicted probability of
the neurological symptoms in type-3 of MND. METHODS: The study design was a
laboratory based cross-sectional discriminative analysis. Patients with MND (N 
106) were assessed for CPT into three groups: MND-mixed (N60), MND-2 (N29),
MND-3 (N17). CPT testing was performed in a standard Quantatative Sensory
Testing laboratory. A one-way ANOVA with post hoc was done for compare the
mean CPT score between the groups. An independent sample t-test was done to
compare the mean CPT and estimated effect size between MND-2 and MND-3
group. The discriminative analysis predicted the group membership in one of the
categories. A binary logistic regressionmodel predicted probability of higher CPT in
MND-3, where CPT score counted as the risk factor to having neurological symp-
toms. A Receiver Operating Characteristic (ROC) curve was created from predicted
probability by binary covariate. RESULTS: Mean CPT differed significantly across
the three groups (F 2, 96  6.69, p  0.002), with a significant higher preference
rating in MND-3 (p  0.004). Moderate discriminates and a small to medium effect
size found between theMND-2 andMND-3. Model discrimination (betweenMND-2
and MND-3) showed 86.2% specificity and 64.7% sensitivity, where an area under
the ROC curvewas 0.836 (95% CI 0.716 - 0.956, p 0.000). CONCLUSIONS: CPT test
was capable of differentiate MND categories. CPT might be a potential tool for
evaluating neurological involvement or hypersensitivity in neck pain.
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OBJECTIVES: Hepatitis C represents a serious Public Health problem. In approxi-
mately 80%of cases, the disease becomes chronic and the diagnosis can sometimes
be made before the disease becomes severe. In 1993, the Brazilian government
adopted a screening system with serological kits for hepatitis C diagnosis in blood
donors. A positive screening, however, should be confirmed with another type of
test since they do not distinguish active infection from past infection. So, molecu-
lar tests are very important to establish actual viremia and the hepatitis c diagno-
sis. Many guidelines throughout the world recommend the molecular test in vari-
ous settings, including the confirmation of HCV in seropositive people. There are
different qualitative molecular tests available for detecting HCV. The aim of this
studywas to conduct a systematic reviewof the accuracy of these different tests for
confirmation of the diagnosis of HCV in seropositive people. METHODS: We
searched MEDLINE, SCOPUS and the Cochrane Library. QUADAS was the tool used
for quality assessment of the studies.RESULTS:The search resulted in 1222 articles
for evaluation. Only 2 studies were included in the systematic review, according to
the established inclusion and exclusion criteria. Both COBAS AMPLICOR and AM-
PLICOR tests had high sensitivity and specificity in one of the studies. The second
study, presented accuracy data regarding an “in house” PCR test, which presented
overall accuracy of 75%. CONCLUSIONS: Although we identified many articles in
our search, the vast majority addressed analytical sensitivity, therefore not meet-
ing our criteria, especially because they did not present accuracy data according to
an established a gold standard. Furthermore, the 2 studies included did not present
a good methodological quality according to QUADAS. These findings show the
urgent need of studies with appropriate design for extraction of accuracy data of
molecular tests.
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OBJECTIVES: The use of K-ras testing in clinical decision-making has grown over
the past few years. The objective of this study was to evaluate, in a real world
context, the trends anddiagnostic findings of K-ras testing usingmanaged care and
EMR data. METHODS: The Georgia Cancer Specialists Database EMR (2005-2010)
and administrative data from theMarketScan and IMPACT database(s) was used to
select patients with newly diagnosed colorectal cancer (CRC). We looked for trends
in use of K-ras in relation to timing of chemotherapy administration. The EMR data
provided information on k-ras mutation type. RESULTS: In MarketScan, of the
23,548 patients with a diagnosis of CRC, 1,730 (7.3%) patients had a test ordered for
K-ras between 2005 and 2010. The number of patients receiving K-ras increased
with line of therapy: first line 336 patients (8.2%) of 4098 treated, second line 455
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